Stockscreener 앱 받기
33.65
2.64%
0.865
시간 외 거래:
33.65
0.005
+0.01%
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia
Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga
Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com
IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com
Ionis reports first quarter 2025 financial results - BioSpace
Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis reports first quarter 2025 financial results | IONS Stock News - GuruFocus
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 EPS Loss $0.93, vs. FactSet Est of $1.10 Loss - marketscreener.com
Polycythemia Clinical Trials, Drugs, Key Companies, - openPR.com
New Harris Poll findings reveal HAE patients are unsatisfied wit - GuruFocus
New Harris Poll: 91% of HAE Patients Desperate for Better Treatments as Current Options Fall Short - Stock Titan
Familial Lipoprotein Lipase Deficiency Market Trends, Size, - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Ionis Pharmaceuticals, Inc. and Akcea Therapeutics Announces the Final Study Results from NEURO-TTR, the Pivotal Study of TEGSEDI™ - marketscreener.com
Familial Amyloid Cardiomyopathy Treatment Market Future - openPR.com
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
0.39%
3.66%
자본화:
|
볼륨(24시간):